What is Adamis Pharmaceuticals Corporation (ADMP) stock price today?

Adamis Pharmaceuticals Corporation (ADMP) is currently trading at $0.78, up 0.85% today.

What is ADMP P/E ratio?

Adamis Pharmaceuticals Corporation's P/E ratio is -0.06. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is ADMP return on equity (ROE)?

Adamis Pharmaceuticals Corporation's return on equity (ROE) is -209.88%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is Adamis Pharmaceuticals Corporation's market cap?

Adamis Pharmaceuticals Corporation has a market capitalization of $7.25M.

NASDAQ · Drug Manufacturers - Specialty & Generic

Adamis Pharmaceuticals Corporation (ADMP) Stock

$0.78 +0.85% NASDAQ: ADMP Healthcare

Valuation

Metric	Value
Price	$0.78
Market Cap	$7.25M
P/E Ratio	-0.06
P/B Ratio	0.00
P/S Ratio	1.45
EPS (TTM)	$-12.24
52-Week High	$21.70
52-Week Low	$0.45
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-209.88%
ROA	-242.23%
ROCE	—
Gross Margin	-60.93%
Operating Margin	-526.88%
Net Margin	-556.72%
Debt/Equity	-0.53
Current Ratio	0.81

Annual Financials (USD)

Metric	2018	2019	2020	2021	2022
Revenue	$15.0M	$22.0M	$17.0M	$2.0M	$5.0M
Operating Profit	$-39.0M	$-29.0M	$-37.0M	$-32.0M	$-25.0M
Net Profit	$-39.0M	$-29.0M	$-49.0M	$-35.0M	$-26.0M
EPS	$-69.86	$-38.52	$-44.57	$-16.80	$-12.24
Op Margin	-261.6%	-131.3%	-225.3%	-1452.0%	-526.9%

Balance Sheet (USD)

Metric	2018	2019	2020	2021	2022
Total Assets	$58.0M	$48.0M	$31.0M	$38.0M	$11.0M
Total Liabilities	$12.0M	$12.0M	$27.0M	$12.0M	$12.0M
Cash	$19.0M	$9.0M	$7.0M	$23.0M	$1.0M
Borrowings	$3.0M	$4.0M	$7.0M	$1.0M	$0

Latest News

Laid Off at 63 Means Retired, Ready or Not. These 4 ETFs Turn Your Severance Into a Salary 24/7 Wall St. · Aug 6, 2026 red violet Announces Pricing of $100 Million Underwritten Public Offering of Common Stock GlobeNewswire · Aug 6, 2026 Police raid South Korea FA in probe into World Cup coach appointment AFP · Aug 6, 2026 Investissement Québec and BDC provide more than $5 million to Altex to accelerate growth across Canada and the United States. CNW Group · Aug 6, 2026 Trex Energy Hyderabad secures 3 awards for energy storage excellence in India PR Newswire · Aug 6, 2026

Cash Flow (USD)

Metric	2018	2019	2020	2021	2022
Operating Cash Flow	$-33.0M	$-20.0M	$-21.0M	$-38.0M	$-26.0M
Investing Cash Flow	$-7.0M	$-6.0M	$-2.0M	$-1.0M	$3.0M
Financing Cash Flow	$37.0M	$12.0M	$20.0M	$54.0M	$285.0M
Net Cash Flow	$1.0M	$-10.0M	$-2.0M	$17.0M	$-22.0M
Free Cash Flow	$-36.0M	$-23.0M	$-22.0M	$-39.0M	$-27.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.03
FCF Yield	-2631774.55%
Quick Ratio	0.70
Interest Coverage	—
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACRDFAcreage Holdings, Inc.	$0.12	+2.52%	-0.01	$4.88M	0.00%
ACRHFAcreage Holdings, Inc.	$0.00	—	-0.01	$4.88M	0.00%
DLTNFDelta 9 Cannabis Inc.	$0.01	-1.95%	-0.05	$3.04M	0.00%
EXDIExactus, Inc.	$0.07	+0.00%	-0.32	$0	0.00%
FLWPFThe Flowr Corporation	$0.00	—	—	$4265	0.00%

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a specialized biopharmaceutical company primarily engaged in the development and commercialization of products within the United States, targeting key therapeutic domains such as allergy, opioid overdose, respiratory conditions, and inflammatory diseases. Its current product portfolio includes SYMJEPI pre-filled epinephrine syringes for the emergency treatment of severe allergic reactions, including anaphylaxis; dry powder inhaler products designed for asthma management; and injectable naloxone for addressing opioid overdose. Additionally, Adamis is advancing pipeline candidates such as APC400, a tempol gel aimed at mitigating radiation-induced dermatitis in cancer patients, and APC410, formulated to treat a range of respiratory ailments including asthma, respiratory syncytial virus (RSV), influenza, and COVID-19. The company also extends its offerings to include corticosteroids, hormone replacement therapies, hospital outsourcing products, and other injectables, alongside a line of veterinary pharmaceutical products. Established in 2006, Adamis Pharmaceuticals Corporation maintains its headquarters in San Diego, California.

Adamis Pharmaceuticals Corporation is headquartered in US.

Adamis Pharmaceuticals Corporation (ADMP) stock trades at $0.78 with a market capitalization of $7.25M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.06, reflecting a net loss over the last twelve months, price-to-book of 0.00, price-to-sales of 1.45. Over the past 52 weeks the stock has ranged between $0.45 and $21.70, and currently trades 96.4% below its 52-week high.

On profitability, Adamis Pharmaceuticals Corporation generates a return on equity (ROE) of -209.88% (not meaningful, as shareholders' equity is negative), an operating margin of -526.88%, a net profit margin of -556.72%.

Official website: www.adamispharmaceuticals.com